Author

Erik Sandvik

Observed names: Erik R Sandvik, Erik Sandvick

Institution: Theravance Biopharma (United States)

Observed institution: Theravance Biopharma (United States)

OpenAlex ID: A5016268164

Telavancin, a Multifunctional Lipoglycopeptide, Disrupts both Cell Wall Synthesis and Cell Membrane Integrity in Methicillin-Resistant Staphylococcus aureus

2005 · Deborah L. Higgins, Ray Chang, et al. · Antimicrobial Agents and Chemotherapy · 426

Development of Gut-Selective Pan-Janus Kinase Inhibitor TD-1473 for Ulcerative Colitis: A Translational Medicine Programme

2020 · William J Sandborn, Deanna D Nguyen, et al. · Journal of Crohn s and Colitis · 88

Concomitant Angiotensin AT1 Receptor Antagonism and Neprilysin Inhibition Produces Omapatrilat-like Antihypertensive Effects Without Promoting Tracheal Plasma Extravasation in the Rat

2011 · Laxminarayan G Hegde, Cecile Yu, et al. · Journal of Cardiovascular Pharmacology · 63

Comparative efficacy of AHU-377, a potent neprilysin inhibitor, in two rat models of volume-dependent hypertension

2011 · Laxminarayan G Hegde, Cecile Yu, et al. · BMC Pharmacology · 6

TD-0903, an inhaled JAK inhibitor in development for COVID-19, blocks ARDS-relevant hyperinflammation and lung injury in primary human immune and airway epithelial cells

2021 · Reuben Sana, Emma Gordon, et al. · 1

In vitro pharmacological characterization of the potent, lung selective pan-JAK inhibitor TD-8236

2019 · Reuben Sana, Whitney Krey-Epstein, et al.

Works count: 6

Citation count: 584

H-index: 4

I10-index: 3